Introduction
============

One decade has passed since the United States Food and Drug Administration (US FDA) determined that implantation of the STAAR Visian Implantable Collamer Lens (ICL, STAAR Surgical, Monrovia, CA, USA) is a safe and effective refractive procedure for the correction of myopia.[@b1-opth-10-1059] Worldwide, the Visian ICL has been marketed for approximately two decades, and over 550,000 lenses have been implanted.[@b2-opth-10-1059] The benefits of the ICL for the correction of moderate-to-high myopia and myopic astigmatism[@b3-opth-10-1059] include predictable, stable refractive correction[@b4-opth-10-1059] and a high efficacy index,[@b5-opth-10-1059] as well as improvement in quality of vision[@b6-opth-10-1059] and quality of life.[@b7-opth-10-1059] Long-term studies have investigated the safety profile of the ICL and demonstrated generally low rates of adverse events.[@b8-opth-10-1059] In a prospective, randomized, study comparing ICL implantation and photorefractive keratectomy, the ICL performed better than photorefractive keratectomy in all measures of safety, efficacy, predictability, and stability, supporting the ICL as a viable alternative to this popular refractive surgical procedure.[@b6-opth-10-1059]

Nevertheless, controversies remain regarding methodology for selection of the implant size, and the relationship of implant size to safety.[@b9-opth-10-1059] In addition, implantation of the US FDA-approved ICL requires that the surgeon perform preoperative laser iridotomies, which means an additional office visit and possible discomfort for patients. A newer design, currently available outside the United States, the V4c Visian ICL with KS Aquaport, VICMO, incorporates a 0.36 mm diameter port in the center of the optic. The presence of this port obviates the need for preoperative iridotomies.

The purpose of this review is to summarize relevant data from publications appearing in the peer-reviewed scientific literature over the decade since FDA approval of the ICL; in particular, to review effectiveness and analyze studies relating to sizing methodology and clinical safety of the ICL V4 models, as well as more recent studies of the safety and effectiveness of the V4c Visian ICL with KS Aquaport, VICMO.

Effectiveness: refractive outcomes
==================================

In a recent editorial, McLeod[@b10-opth-10-1059] noted that phakic lenses such as the ICL: "Can provide optically superb correction of relatively high degrees of ametropia that lie well beyond the recommended range for keratorefractive procedures, such as laser in situ keratomileusis and photorefractive keratectomy.[@b10-opth-10-1059]"

He cited, for example, the report from Igarashi et al[@b11-opth-10-1059] demonstrating excellent long-term refractive results in a population of patients with baseline manifest refractive spherical equivalent (MRSE) −10.19±2.86 D: mean logMAR uncorrected distance visual acuity 0.02±0.33 and 73.2% of eyes with uncorrected distance acuity of 20/20 or better 8 years after surgery.

Large cohort studies with long-term follow-up have found similar results. In a report of 3-year follow-up of 526 eyes of 294 patients with mean preoperative MRSE of −10.06±3.74 D participating in the US FDA clinical trial of the ICL, 59.3% had 20/20 or better uncorrected visual acuity (UCVA), and 94.7% had 20/40 or better UCVA if best-corrected visual acuity was 20/20 and they were targeted for emmetropia; 67.5% of patients were within 0.5 D and 88.2% were within 1.0 D of predicted refraction.[@b4-opth-10-1059] Lee et al[@b12-opth-10-1059] reported 281 eyes of 145 patients who were followed for at least 5 years (mean =87±18.9 months) and had mean preoperative MRSE of −8.74±2.27 D (−4.00 to −15.25 D). They noted 60.5% UCVA 20/20 or better: "At the end of follow up, the postoperative logMAR uncorrected distance visual acuity (UDVA) was 0.30 (approximately 6/12) or better in 254 eyes (90.4%), 0.10 (approximately 6/7.5) or better in 238 eyes (84.7%) and 0.00 (6/6) or better in 170 eyes (60.5%)."

Alfonso et al[@b13-opth-10-1059] reported 5-year follow-up of 188 eyes of 111 patients. The authors noted that: "The mean spherical equivalent decreased from −11.17±3.40 D preoperatively to −0.23±0.50 D 1 month postoperatively (95% confidence interval \[CI\], −0.15 to −0.02) and −0.88±0.72 D at 5 years (95% CI, −0.68 to −1.09).Furthermore,High levels of predictability were achieved early after surgery; 163 eyes (86.7%) were within ±0.50 D and 182 eyes (96.8%) were within ±1.00 D of the attempted correction at the 1-month visit. The improvement was maintained over the postoperative follow-up (*r*^2^=0.953 at 5 years)."

These results are representative of those reported in the literature as a whole and underscore the efficacy of ICL implantation. As Price and Price[@b3-opth-10-1059] noted in their recent evaluation of the toric ICL for simultaneous treatment of myopia and astigmatism, "Postoperatively, 77% of treated eyes had uncorrected visual acuity (UCVA) that equaled or exceeded the preoperative best spectacle corrected visual acuity (BSCVA). At 1 year, UCVA was ≥20/20 in 83% of treated eyes and ≥20/40 in 96%.[@b3-opth-10-1059]"

Refractive outcomes such as these support McLeod's[@b10-opth-10-1059] description of "optically superb correction."

Effectiveness: quality of life and patient satisfaction
=======================================================

Myopia significantly impacts quality of life. As Rose et al[@b14-opth-10-1059] pointed out in their investigation of quality of life in myopia, "In many this led to a lack of self confidence because of teasing and feelings of inadequacy; this, in turn, could lead to social isolation and difficulties forming relationships.[@b14-opth-10-1059]"

Perhaps unsurprisingly, these authors found that the adverse effects of higher degrees of myopia are comparable to a disabling disease such as keratoconus. It stands to reason that correction of myopia is, therefore, likely to engender significant improvement in quality of life.

Improvement in quality of life following ICL implantation has been investigated by Ieong et al,[@b7-opth-10-1059] who reported that "Implantable Collamer lens implantation provided significant gains across a broad range of life activities and is clearly a life changing intervention for many patients with high myopia." Kobashi et al[@b15-opth-10-1059] compared quality of life following ICL implantation in patients with mean preoperative MRSE −9.97±2.51 D (range, −3.00 to −14.50 D) to that following laser-assisted in situ keratomileusis (LASIK) in patients with mean preoperative MRSE −6.31±2.20 D (range, −3.00 to −12.88 D), and reported, "The scores for activity limitations, symptoms, appearance, and satisfaction with correction were significantly higher in the phakic intraocular lens (pIOL) group than in the LASIK group." They concluded that: "Phakic IOL implantation may offer significant vision-related quality-of-life advantages (eg, fewer activity limitations and symptoms and better appearance and satisfaction with correction) over wavefront-guided LASIK for myopia in the long term."

Marked improvements in UCVA and substantial gains in quality of life create a strong incentive to consider ICL implantation. These outcomes should be considered in light of safety, to determine whether the expected benefits outweigh the potential risks.

Safety and sizing
=================

The ICL is intended for surgical implantation within the posterior chamber of the eye, behind the iris and in front of the crystalline lens. Different sizes of overall diameter are manufactured to accommodate normal variations in intraocular anatomy (eg, 12.1, 12.6, 13.2, and 13.7 mm). The relationship of the selected overall diameter of the implanted lens to the dimensions of the posterior chamber represents an important determinant of the achieved postoperative vault, which is the term used to describe the measurable distance between the anterior capsule of the crystalline lens and the posterior surface of the ICL.

There has been considerable interest in finding ways to improve sizing, ie, the selection of the best-fit overall diameter of ICL for a given eye, because optimal sizing is seen as a way to increase the proportion of ICLs within the range of safe vault. The clinical significance of vault outside of the range of safety resides in the risk of specific adverse events, including pupillary block, anterior subcapsular (ASC) cataract, pigment dispersion and glaucoma. Precise definitions for insufficient vault and excessive vault have, however, remained elusive, because only a percentage of eyes with vault beyond any predefined range experiences vault-related adverse events. While insufficient or excessive vault may be recognized by the occurrence of specific adverse events, eyes with the same degree of vault do not experience these adverse events. Thus, extremes of vault must be viewed as risk factors for adverse events, not as adverse events in and of themselves.

Safe ranges of vault
====================

Authors have reported a range of values for the limits of safe vault, based on the likelihood that cataract or pupillary block may occur beyond that range. For example, Gonvers et al,[@b16-opth-10-1059] whose study included both the earlier V3 model as well as V4 ICLs, reported in 2003 that: "20 eyes with anterior subcapsular cataracts (ASCCs) had central vaulting equal to or less than 0.09 mm. Among the 55 eyes with clear lenses, 26 had vaulting equal to or less than 0.09 mm (11 of these had no vaulting).[@b16-opth-10-1059]"

Thus, although vault ≤90 μm was a risk factor for the development of ASC cataract in this series, the majority of eyes with vault in this range maintained clear lenses.

The authors reported that: "Myopia was more pronounced in the ASCC group: The mean power of the implanted ICLs was −17.6±2.9 D (range −11.5 to −21.0 D) in the 20 eyes with ASCCs and −14.9±3.3 D (range −8.5 to −20.5 D) in the 26 eyes with clear lenses.[@b16-opth-10-1059]"

Therefore, data supported the conclusion that low vault, along with higher levels of myopia, constituted risk factors for ASC cataract (of note, this series included a relatively greater proportion of higher myopia than most others in the literature, with a mean refraction of −16.5±3.3 D \[range, −8.5 to −21.0 D\]).

Gonvers et al[@b16-opth-10-1059] concluded that 150 μm should be regarded as a lower limit of safe vault, noting that: "We believe 0.15 mm in central vaulting should be targeted in future implantations, even though this is greater than the 0.09 mm vaulting below which (*sic*) no anterior subcapsular cataracts (ASCCs) were found in our series."

The rationale given for the higher level of central vault was that: "When the central vaulting was equal to or greater than 0.15 mm (approximately 1.5 the central thickness of the optic), there was no contact (at least up to the midperiphery of the ICL) between the ICL and the crystalline lens regardless of the ICL model.[@b16-opth-10-1059]"

Schmidinger et al,[@b17-opth-10-1059] whose study also involved earlier V3 as well as V4 model ICLs, reported mean vaulting of 216±104 μm at the initial manifestation of ASC cataract and 98±100 μm at the time of cataract extraction. These authors noted a gradual shallowing of vault over time equal to 28 μm per year, "close to the mean yearly increase in the crystalline lens rise (20 μm)." They concluded that "it would be advisable to adhere to a minimum central vaulting of 230 μm."

Zeng et al[@b18-opth-10-1059] suggested a safe range of vault from 100 to 1,000 μm.

Rayner et al[@b19-opth-10-1059] reported a "generally accepted" lower limit of 50 μm, and no specific upper limit, as long as the anterior chamber angle "structure and function remain normal." Bhikoo et al[@b20-opth-10-1059] initially suggested a lower limit of 200 μm, but later revised this limit to 150 μm. In their study of 147 eyes of 80 patients, Lisa et al[@b21-opth-10-1059] noted that: "\[...\] eyes with vault values from 100 to 200 μm (approximately 8%) and from 900 to 1,000 μm (approximately 1.5%) were followed closely.[@b21-opth-10-1059]"

Dougherty et al[@b9-opth-10-1059] suggested a safe range of vault from 90 to 1,000 μm.

Maeng et al[@b22-opth-10-1059] retrospectively reviewed charts of 233 eyes of 134 patients implanted with ICLs and found 26 eyes of 20 patients with low vault defined as 250 μm or less. They reported cataract development in eight eyes of six patients, representing "3.4% of all 233 eyes; 30.8% of 26 eyes with low vaulting".[@b22-opth-10-1059] Anterior subcapsular cataract was reported in seven of the eight eyes, and cataract surgery was required in five of the eight eyes, a mean of 33.2±14.3 months after implantation.[@b22-opth-10-1059]

Of note, the vaulting values in the cataract group were statistically significantly lower than in the group without cataract at all follow-up times. The authors concluded that: "The optimum cutoff values that could be used to divide patients into a high-risk group and a low-risk group for cataract development were vault, 51.7 μm; age 45 years; and preoperative spherical equivalent (SE), −14.00 D (*P*=0.0095, *P*=0.0367, and *P*=0.0342, respectively).[@b22-opth-10-1059]"

As the foregoing discussion demonstrates, the authors have placed the lower limit of safe vault from approximately 50 to 250 μm, and the upper limit from approximately 1,000 μm upward, as long as the anterior chamber angle structure and function remain normal. These estimates of safe ranges based on the incidence of complications above or below certain thresholds of vault emphasize the conclusion that insufficient or excessive vault should be considered a risk factor, not a complication, and that only a percentage of eyes with vault beyond any predefined range experiences vault-related adverse events.

Biometry
========

Selection of ICL size is most commonly based on anatomic measurement of the corneal white-to-white (WTW) horizontal diameter and the anterior chamber depth (ACD). Alternative sizing methodologies employ measurement of the sulcus-to-sulcus diameter (STS), the angle-to angle diameter (ATA), or the iris pigment end-to-pigment end diameter (PTP). The precision and accuracy of the technologies employed in obtaining these measurements should be considered in any discussion of sizing.

WTW is measured with calipers or, more recently, imaging technology such as Scheimpflug photography or scanning slit topography.[@b23-opth-10-1059],[@b24-opth-10-1059] Methods of measuring WTW include manual calipers and a variety of imaging devices such as Orbscan (Bausch & Lomb, Rochester, NY, USA), IOL Master (Carl Zeiss Meditec, Jena, Germany), Pentacam (Oculus, Irvine, CA, USA), and Lenstar (Haag Streit, Koeniz, Switzerland). Although automated measurement of WTW is convenient and repeatable, it is not necessarily more accurate than measurement with manual calipers. The various devices use different optical principles for the automatic detection of physical landmarks, so variation in results is not surprising. Validation with manual calipers can help surgeons avoid detection errors due to anomalies in the limbal area such as arcus senilis, pigmentation, pinguecula, and neovascularization, which is particularly common among highly myopic contact lens wearers.

ATA and PTP are measured with optical coherence tomography (OCT).[@b25-opth-10-1059] STS is measured with ultrasound biomicroscopy (UBM).[@b26-opth-10-1059] There have been a number of articles assessing the variance and repeatability of measurements with various UBM devices. For example, Pop et al[@b27-opth-10-1059] found a standard error of 0.4 mm and reproducibility of 79% with 50 MHz UBM. They found that measurement of the sulcus with UBM had greater variation than measurement of WTW with calipers, and concluded that "If precision below 0.4 mm is required for ICL sizing, UBM may not be the best method of measuring the sulcus."

Oh et al[@b28-opth-10-1059] found that the coefficient of variation for intraobserver sulcus diameter measurements with 35 MHz UBM was 0.90%, demonstrating "high reliability." However, they measured a vertically oval sulcus shape, in contradistinction to Rondeau et al,[@b29-opth-10-1059] who used a prototype 50 MHz UBM and determined that "the longest diameter clusters in the horizontal plane\[...\]" Rondeau et al[@b29-opth-10-1059] also found a coefficient of variation of 0.90%, with standard deviation of approximately 100 μm. Reinstein et al[@b30-opth-10-1059] reported within-eye repeatability of 0.23 mm and population standard deviation of 0.69 mm for sulcus diameter. Guber et al[@b31-opth-10-1059] utilized the HiScan 35 MHz UBM and found that measures were less repeatable than expected, with a within-subject standard deviation for repeated measures with the same observer (Sr) of 0.39 mm between any two images and a 95% confidence interval (CI) of ±0.76. The Sr improved to 0.15 mm when the average of two measures was used. Therefore, they concluded, "it is safe to assume that the repeatability is \<0.15 mm when the average of four or more images was used." Yokoyama et al[@b32-opth-10-1059] found a mean coefficient of variation of 0.62% with the Sonomed 35 MHz UBM.

Although the intraexaminer variance was low in these studies, Yokoyama et al[@b32-opth-10-1059] also found that interexaminer variance was high. The 95% CI of the interexaminer error was −1.09 to 1.52 mm. The authors identified several potential sources of error in these measurements, including misdirection of scanning, contraction of the ciliary muscle, image selection, unclear visualization of the ciliary sulcus, and irregularities in the ciliary sulcus. In conclusion, the authors state, "This amount of variance cannot be ignored in a clinical setting."[@b32-opth-10-1059]

In general, measurements of WTW, ATA, PTP, and STS do not correlate highly,[@b28-opth-10-1059],[@b30-opth-10-1059],[@b33-opth-10-1059] although some authors have found varying degrees of correlation.[@b34-opth-10-1059] These anatomic relationships, while of scientific interest, are only clinically relevant in so far as their utilization may increase the safety of ICL implantation.

Literature review of objectively measured vault: methods
========================================================

As noted, ICL sizing and its relationship to achieved ICL vault have generated significant clinical interest. To gain a better understanding of current sizing methodologies and their relationship to achieved vault and complications, we conducted a literature search utilizing two databases, [PubMed.gov](http://PubMed.gov) and Science.gov, using the following search criteria: original papers in English published from 2006 to 2015,prospective or retrospective case series,studies utilizing manufacturer recommended sizing nomogramsstudies developing nomograms based on reported clinical data,studies reporting data on currently available (ie, V4) Visian ICL models for myopia or myopia and astigmatism,studies generally following approved indications for use (eg, ACD ≥3 mm), andstudies providing descriptive statistics of objectively measured vault.

Case reports, studies of specific disease entities (eg, keratoconus), case series only presenting vault data for eyes with complications (eg, cataract, elevated intraocular pressure \[IOP\]), and case series only providing vault data for a subset of subjects (eg, those with toric IOL rotation) were excluded.

The search terms were "STAAR" or "Visian" or "phakic ICL" or "implantable ICL" or "phakic implantable collamer lens" or "implantable collamer" or "implantable contact lens" and "vault."

A total of 112 publications were returned and reviewed individually for relevance. In addition, references cited in these publications were examined for potential relevance. [Table 1](#t1-opth-10-1059){ref-type="table"} provides a list of the 22 peer-reviewed, published studies that met the aforementioned criteria, with the sizing methods studied and descriptive statistics of the reported achieved vault.

Reported sizing methodologies
=============================

The studies reporting vault based on WTW and ACD measurements generally employed the manufacturer's sizing nomogram and reported data on a total of 2,263 eyes. The authors' methods state, for example, that "size was determined based on the horizontal WTW distance and ACD, measured with the Orbscan II device following the manufacturer's recommendations"[@b13-opth-10-1059] or "The ICL diameter was individually determined based on the horizontal WTW distance and ACD measured with Orbscan II (Bausch & Lomb, Rochester, NY) following the manufacturer's recommendations"[@b35-opth-10-1059] or "The size of ICL was also chosen by the manufacturer based on the horizontal corneal diameter and ACD"[@b36-opth-10-1059] or "The size of the ICL was also chosen by the manufacturer on the basis of the horizontal corneal diameter and the ACD measured by scanning-slit topography (Orbscan IIz)".[@b11-opth-10-1059]

Studies employing STS-based sizing reported data on 204 eyes. Authors reported unique nomograms based on regression analysis, for example, "developed using statistical analysis and clinical judgment,"[@b9-opth-10-1059] or employing a trigonometric formula that included "measurements of ACD and sulcus diameter, the elongation factor of the collamer material, and the base-curve of the ICL model."[@b37-opth-10-1059] The single study employing PTP-based sizing included data on 29 eyes and "included 2 stages as follows: (1) comparison of measurements performed by UBM and AS-OCT (suggested new algorithm) and (2) clinical evaluation of the effectiveness of the proposed algorithm for measuring the distance from iris pigment end to iris pigment end.[@b25-opth-10-1059]"

Meta-analysis of sizing: results
================================

Comparison of the descriptive statistics for vault reported in the selected studies, as listed in [Table 1](#t1-opth-10-1059){ref-type="table"}, demonstrates a great deal of similarity in achieved vault regardless of sizing methodology, and an acceptable range of vault in the vast majority of subjects. For example, the mean vault includes values from 370 to 640 μm for STS-based sizing, and from 322 to 594 μm for WTW/ACD-based sizing. Standard deviations extend from 160 to 250 μm for STS-based sizing, and from 141 to 268 μm for WTW/ACD-based sizing. The reported range of vault extends from 0 to 1,300 μm for WTW/ACD-based sizing (Alfonso et al[@b38-opth-10-1059] reported both of these extreme values in their series of 452 eyes). For studies on STS-based sizing, the reported range of vault is 80--1,330 μm.

The forest plot provided in [Figure 1](#f1-opth-10-1059){ref-type="fig"} demonstrates the variability of vault within and among studies. Achieved vault based on STS and WTW sizing methods are not statistically significantly different (two-sample two-sided *t*-test using pooled mean and standard deviations; *t* (2,594)=1.33; *P*=0.18). The difference in mean (STS minus WTW) is 20 μm. The 95% CI for the difference is −10 to 50 μm.

Considering a conservatively safe range of vault from 250 to 1,000 μm and assuming a normal distribution of vault, 13% of STS eyes would have vault between 0 and 250 μm, and 0.5% of STS eyes would have vault above 1,000 μm. Similarly, 16% of WTW eyes would have vault between 0 and 250 μm, and 0.4% of WTW eyes would have vault above 1,000 μm. [Figure 2](#f2-opth-10-1059){ref-type="fig"} provides a graphic representation of the pooled vault data, showing the relative congruence of achieved vault with WTW and STS. In summary, no clinically meaningful or statistically significant difference in achieved vault differentiates WTW- and STS-based sizing methodologies.

Critiques of sizing methodology
===============================

A few authors have suggested improved sizing with STS compared to WTW, based on comparisons of clinically measured vault following implantation with STS-based sizing versus theoretical back-calculation of expected vault based on sizing calculated from WTW and ACD. However, the demonstrated variability in achieved vault with all methods of sizing as shown in the published literature appears to render theoretical back-calculation of predicted vault a somewhat questionable methodology.

For example, Reinstein et al[@b37-opth-10-1059] compared achieved vault with STS sizing to the theoretical vault that would have been achieved with WTW sizing using a "gap" constant to represent the distance between the sulcus and the ICL haptic, and reverse circle trigonometry to predict the vault height that would have occurred if a different size lens had been selected. Similarly, Kojima et al[@b26-opth-10-1059] compared achieved vault to "predicted" vault with WTW sizing (but did not specify the methodology of their prediction). Dougherty et al[@b9-opth-10-1059] reported the number of times a different size would have been selected with WTW sizing compared with STS sizing. However, the observation that sizing based on STS may produce different results in terms of the recommended ICL diameter compared to sizing based on WTW and ACD does not controvert the evidence that both methods produce very similar means, standard deviations, and ranges of measured postoperative vault.

Lee et al[@b39-opth-10-1059] examined the relationship of patient age, ICL overall diameter, ICL optical power, and biometric parameters (STS, WTW, K-reading, and ACD) with achieved vault. They concluded, "In the present study, the postsurgical achieved vault could be explained in only approximately 36.9% of the cases, as determined by multiple regression analysis, which included ICL size, age, and preoperative biometric results, such as STS, as independent variables.[@b39-opth-10-1059]"

Therefore, as these authors state, the variability of vault regardless of sizing methodology probably reflects unmeasurable ocular characteristics such as "vertical compression by the iris and dampening effect of the ciliary sulcus structure". The demonstrated variability of vault regardless of sizing methodology may be due to unmeasurable anatomic and physiologic factors affecting the relationship of the ICL and the posterior chamber.

Two studies, one by Choi et al[@b40-opth-10-1059] and another by Ghoreishi et al,[@b41-opth-10-1059] have compared clinical results with STS and WTW sizing. Choi et al[@b40-opth-10-1059] reported a small retrospective study in which sizing based on STS was compared with sizing based on WTW; however, this study could not be included in the meta-analysis because the authors did not report descriptive statistics of vault, reporting instead the numbers of cases within "the ideal range (250--750 μm)." Because the UBM device utilized by these authors gave only a partial view of the sulcus, the STS distance was determined by first creating physical epithelial dimples on the limbus at 3 o'clock and 9 o'clock that could be imaged with ultrasound. An imaginary vertical (ie, paraxial) line was then drawn on the ultrasound image from each dimple to the posterior iris pigment epithelium. The horizontal (ie, coronal) distances from this line to the ciliary sulcus at 3 o'clock and 9 o'clock were added to the WTW as measured by Orbscan or caliper. Using this method, 13 of 13 eyes achieved vault within the ideal range; however, utilizing only WTW, nine of 17 eyes achieved ideal vault. One eye in the WTW group underwent ICL exchange for insufficient vault (90 μm) at 6 months postoperatively.

Ghoreishi and Mohammadinia[@b41-opth-10-1059] prospectively compared vault based on randomization to sizing based on either WTW ("WTW value was entered into the ICL calculation formula which was proposed by the manufacturer") or STS ("ICL size was ordered based on horizontal sulcus-to-sulcus measurement"). In a third, nonrandomized group, sizing was based on an average of WTW and STS ("M group"). The mean, standard deviation, and range of vault in the WTW group were 368.57±165.661 μm (range, 100--750 μm), while in the STS group they were 365.40±207.735 μm (range, 110--1,010 μm) and in the third group they were 411.43±217.21 μm (range, 80--1,010 μm). In the WTW group, 77% of eyes had acceptable or ideal vault according to the authors' criteria, compared with 76% in the STS group. In the third group, only 40% had acceptable or ideal vault; however, there were no statistically significant differences in achieved vault among the three groups.

Ghoreishi and Mohammadinia[@b41-opth-10-1059] concluded, "\[...\] STS measurement, by itself, did not improve the ICL sizing results in our study.[@b41-opth-10-1059]"

In sum, Ghoreishi and Mohammadinia,[@b41-opth-10-1059] in their randomized prospective study, reported no clinically meaningful nor statistically significant difference in achieved vault between WTW- and STS-based sizing methods.

While the quest for improved predictability of vault based on different imaging technologies may appear to represent an appealing endeavor, it has not resulted in a demonstrable reduction in the variability of achieved vault or in the already low rate of complications that occur following ICL implantation. Those studies included in the literature review that specifically reported complications, including studies utilizing WTW/ACD, STS, and/or PTP methodologies, included data from 1,387 eyes followed for up to 10 years. The overall rate of secondary surgical intervention was 0.8% ([Table 2](#t2-opth-10-1059){ref-type="table"}), indicating a low rate of complications. Replacement of the ICL was performed in six eyes (0.4%), asymptomatic ASC cataracts were observed in four eyes (0.3%), and cataract surgery was performed in one eye (0.1%). There were no reported cases of pupillary block or glaucoma.

In summary, no methodology has proven superior in terms of the predictability of vault to the use of WTW and ACD, which remains the most popular and best-studied technique.

Complications of ICL implantation
=================================

Several authors who did not report descriptive statistics for objective vault and whose work was therefore excluded from the meta-analysis have, however, reported rates of secondary surgical intervention related to insufficient vault in the presence or absence of cataract formation, and excessive vault in the presence or absence of elevated IOP, and therefore merit inclusion in this review.

ICL replacement
===============

In their study of lens exchange, Zeng et al[@b18-opth-10-1059] adopted criteria for exchange as follows: vault less than 100 μm or direct contact between the ICL and the crystalline lens; or vault greater than 1,000 μm and shallow anterior chamber with angle closure in any quadrant, or vault greater than 1,000 μm without angle closure but pupil diameter larger than preoperative and unrelieved patient-reported glare.

In a cohort of 616 eyes of 337 patients implanted with ICLs sized according to WTW and ACD measurements, 16 eyes of 15 patients (2.6%) met the authors' criteria for lens replacement. Of these 16 replacements, eight were indicated for insufficient vault, while eight were indicated for excessive vault.

For comparison, in the US FDA investigational device study of the Visian ICL, in which sizing was also performed based on WTW and ACD, although criteria for surgical intervention may have differed, ICL replacement for insufficient or excessive vault was reported in five of 526 eyes (1.0%): "Two (0.4%) ICLs were replaced, because they were too long (at 2 and 3 days postoperatively); two (0.4%) ICLs were replaced because they were too short (at 3 weeks and 17 months)" and "one (0.2%) ICL was replaced for a longer lens (at 26 months postoperatively)."[@b42-opth-10-1059] The small proportion of eyes with either insufficient or excessive vault in both the study by Zeng et al[@b18-opth-10-1059] and the US FDA report were similar, suggesting that the sizing nomogram appropriate ly targets the median.

Rayner et al[@b19-opth-10-1059] reported replacing ICLs, which had been sized using WTW and ACD, in two of 126 eyes of 68 patients (1.6%) for excessive vault on the basis of somewhat different criteria from those of Zeng et al:[@b18-opth-10-1059] "Generally accepted limits of ICL vaulting are around 50 μm (just visible gap), and no specific upper limit as long as angle structure and function remains normal.[@b19-opth-10-1059]"

Bhikoo et al[@b20-opth-10-1059] used WTW and ACD for sizing the Toric ICL (TICL), and noted, "Anterior chamber depth and horizontal limbal 'white-to-white' distances were measured with the Orbscan corneal topographer. A variety of alternative technologies can also be used to determine these measurements -- there is no agreement as to the optimal technology to use.[@b20-opth-10-1059]"

These authors replaced one ICL for "low vault" of 180 μm out of 72 eyes operated (1.4%). The authors noted that they subsequently changed their criterion for replacement to vault \<150 μm.

In summary, ICL exchange for insufficient or excessive vault in the absence of complications remains a matter of medical judgment. On the other hand, excessive vault in the presence of compromised anterior chamber angle function and insufficient vault in the presence of visually significant cataract are indications for surgical intervention.

Cataract
========

Several authors whose work was excluded from the literature review of objective vault have provided additional data regarding the development of cataract following ICL implantation. For example, Lee et al[@b12-opth-10-1059] reported data on 281 eyes of 145 patients who underwent ICL implantation and had follow-up of at least 5 years (87±18.9 months). Their paper was excluded from the literature review because they did not provide objective measurement of postoperative vault, using instead the commonly applied clinical method of classifying vault into five levels by comparing the separation between the anterior surface of the crystalline lens and the posterior surface of the ICL to the corneal thickness using an optical section during routine slit-lamp examination. Six eyes (2.1%) developed asymptomatic ASC cataracts that had not required cataract surgery by the last visit, in which one eye (0.3%) showed no change in best corrected logMAR visual acuity (BCVA) and five eyes (1.8%) lost two lines. Although no eye required cataract surgery, the patients were scheduled for closer follow-up.

In a large retrospective study, Alfonso et al[@b43-opth-10-1059] reported on 3,420 eyes of 1,898 patients who underwent implantation with the ICL V4, V4b, or V4c (V4 and V4b have similar designs, differing only in storage solution, ie, sodium chloride or balanced salt solution); follow-up varied from 6±2 years (range, 1--12 years) to 2.0±0.5 years (range, 1--3 years) and to 6±4 months (range, 3--24 months), respectively. Twenty-one eyes (0.61%) had explantation for ASC cataract, and the mean time between ICL implantation and cataract surgery was 4.2±1.8 years (range, 1--7 years). Although the authors did not provide descriptive statistics for vault in the entire population (and, therefore, their paper was excluded from the literature review), they did note that: "The mean vault in eyes that developed cataracts was 103±69 μm (range 40 to 270 μm); in 15 eyes (70%) the vault was less than 100 μm, and in 6 eyes (30%) the vault was between 100 μm and 270 μm."

In their 5-year retrospective study, Brar et al[@b44-opth-10-1059] reported that, out of a total of 957 eyes, four eyes (0.4%) had explantation for ASC cataract, and an additional four eyes (0.4%) had explantation for nuclear or posterior subcapsular cataract. Thus, 50% of cataracts were not related to the ICL. Mean time between ICL implantation and cataract surgery was 65.5±24.1 months. Although the authors did not report descriptive statistics for vault for their entire subject population, they did note that six eyes (0.6%) had ICL exchange for excessive vault, and five eyes (0.5%) had ICL exchange for frequent rotation of a toric lens, which was associated with insufficient vault.

Igarashi et al[@b11-opth-10-1059] reported on 41 eyes implanted with the V4 ICL after 8 years of follow-up. While four eyes (9.8%) developed asymptomatic ASC cataracts, an additional four eyes (9.8%) developed asymptomatic nuclear cataracts, which are unrelated to the ICL. Two eyes (4.9%) had explantation for cataract; however, the authors did not specify the type of cataract present in these cases. The relatively older age of subjects at the time of implantation in the study by Igarashi et al[@b11-opth-10-1059] (37.3±10.2 years, range, 21--55 years) likely predisposed them to a higher incidence of cataract.

In fact, baseline age was a risk factor for cataract development in the US FDA investigational study of the ICL.[@b8-opth-10-1059] Of 209 eyes of subjects ≥40 years at the time of ICL implantation, six (2.9%) developed clinically significant cataracts by 5 years postoperative. In contrast, cataract developed in only one (0.3%) of the 317 eyes of subjects \<40 years of age (*P*\<0.02 with Fisher's exact test). These findings support the conclusion that cataract also occurs more frequently following ICL implantation in patients of older age.

The association of increasing cataract with age is expected, with very large relative risk found with advancing age in multiple epidemiological studies.[@b45-opth-10-1059]--[@b48-opth-10-1059] The overall frequency of visually significant cataract in the worse eye of patients without a history of intraocular surgery aged 43--54 has been reported as 1.6% (2.6% in women and 0.4% in men).[@b49-opth-10-1059]

Schmidinger et al[@b17-opth-10-1059] noted the association of insufficient vault with ASC cataract, and described a 17% rate of cataract surgery after 10 years of follow-up. This relatively high rate of cataract may be related to the higher degree of myopia treated by these authors, who reported a mean spherical equivalent of −16.4±5.4 D (range, −5.5 to −29.0 D) among eyes of subjects implanted with the V4 ICL (n=84). Long-term follow-up by other authors suggests that higher myopia is a risk factor for the development of visually significant cataract following ICL implantation. Of note, high myopia is also a risk factor for cataract in patients without any history of intraocular surgery.

Gonvers et al,[@b16-opth-10-1059] who used earlier model ICLs, first reported in 2003 that "\[...\] myopia was more pronounced in the ASCC group: The mean power of the implanted ICLs was −17.6±2.9 D (range −11.5 to −21.0 D) in the 20 eyes with ASCCs and −14.9±3.3 D (range −8.5 to −20.5 D) in the 26 eyes with clear lenses.[@b16-opth-10-1059]"

With regard to the incidence of cataract reported by Gonvers et al,[@b16-opth-10-1059] it is relevant to note the relatively low mean vault described at 3 months postoperative for the 51 V4 ICLs implanted in their study, "mean 0.12±0.11 mm; range 0 to 0.37 mm." The low mean vault explains the relatively higher frequency of eyes with ASC opacities reported in this study, 27% with follow-up of 24±7 months (range, 12--34 months). These data support the conclusion that low vault, together with higher levels of myopia, constitute risk factors for ASC cataract.

Sanders[@b8-opth-10-1059] also reported the association of higher myopia with the development of visually significant ASC cataract based on data from the postapproval continuation of the Visian ICL clinical study. He noted that while the mean preoperative spherical equivalent refraction of seven eyes that developed clinically significant cataracts was −16.40 D (range, −12.75 to −20.00 D), the mean spherical equivalent of the entire cohort (n=526) was −10.10 D (range, −3.00 to −20.00 D). Additionally, while clinically significant cataracts occurred in seven (6.6%) of 106 eyes with preoperative myopia of −12.00 D or higher, none occurred in the 420 eyes with preoperative myopia lower than −12.00 D (*P*\<0.0001 with Fisher's exact test). These data support the conclusion that cataract occurs more frequently in patients with a higher degree of myopia at baseline.

Of note, other types of cataract have also been shown to occur more frequently in the setting of higher myopia. Although the association of myopia with nuclear cataract is confounded by the increased index of refraction of the lens, preexisting myopia related to axial length has been associated with an increased incidence of nuclear and posterior subcapsular cataract at an earlier age.[@b50-opth-10-1059]--[@b52-opth-10-1059] In particular, posterior subcapsular cataract has been associated with deeper anterior chamber, thinner lens, and a longer vitreous chamber.[@b53-opth-10-1059] The 10-year incidence of cataract surgery among patients with moderate-to-high myopia (−3.5 D or higher) has been reported as 22% in a population aged ≥49 years.[@b54-opth-10-1059] For comparison, the rate among emmetropes in the same population was 9.2%. Potential mechanisms leading to early cataract in high myopia are largely undetermined, but some have hypothesized that retinal lipid peroxidation might play a key role.[@b55-opth-10-1059]

Guber et al[@b56-opth-10-1059] recently reported data from a cohort of 133 eyes of 78 patients, of which 75 eyes (56.4%) from 45 patients were examined 10 years after ICL implantation: "The rate of lens opacity development was 40.9% (95% CI, 32.7%−48.8%) and 54.8% (95% CI, 44.7%--63.0%) at 5 and 10 years, respectively.[@b56-opth-10-1059]"

The authors note that the relatively high incidence of lens opacities observed may have been related to their use of Scheimpflug photography and "full dilation." On the other hand, the relatively higher incidence of cataract surgery reported in this study may be related primarily to older age and higher myopia. Twenty-five percent of the subjects in Guber's study were over 45 at the time of ICL implantation, and 50% of the subjects had greater than −12 D of myopia.

Unfortunately, Guber et al[@b56-opth-10-1059] did not report the types of lens opacities that developed nor the types of cataracts that required surgery. In other studies, eg, those published by Igarashi et al[@b11-opth-10-1059] and Brar et al,[@b44-opth-10-1059] nuclear sclerosis and posterior subcapsular cataract -- unrelated to the ICL -- are noted to account for half of asymptomatic lens opacities or visually significant cataracts in patients implanted with the ICL. Therefore, the true rate of cataract surgery secondary to ICL implantation in the cohort reported by Guber et al[@b56-opth-10-1059] remains uncertain.

[Table 3](#t3-opth-10-1059){ref-type="table"} summarizes information on the incidence of lens opacities and cataract surgery from long-term studies of ICL implantation. In the context of these ten publications, which present data on 5,477 eyes followed for up to 10 years, the relatively higher incidences of opacities and cataract surgery in the reports by Schmidinger[@b17-opth-10-1059] and Guber[@b56-opth-10-1059] (n=159) appear to represent outliers. Excluding these reports, the incidence of ASC opacities ranges from 1.1% to 5.9%, and the incidence of ASC cataracts requiring surgery ranges from 0% to 1.8%. Higher myopia in Schmidinger et al,[@b17-opth-10-1059] and a relatively older population and higher myopia in Guber et al,[@b56-opth-10-1059] may help explain their higher rates of reported lens opacities and cataracts.

Pigment dispersion glaucoma
===========================

As listed in [Table 2](#t2-opth-10-1059){ref-type="table"}, there was a zero incidence of pigment dispersion, ocular hypertension, or glaucoma reported in the publications included in the meta-analysis of vault. Pigment dispersion glaucoma has generally been considered to be related to excessive vault; however, Guber et al[@b56-opth-10-1059] noted normal vault ("403 μm on a mean of 190--740 μm \[sic\]") among "16 cases of ocular hypertension controlled with IOP-lowering treatment, developing a mean of 7.3 years (range, 1.4--12 years) after implantation."[@b56-opth-10-1059] These cases were associated with pigmentation "observed in the iridocorneal angle;" however, the authors did not specify whether the pigmentation was noted to increase over time, or was different from pigmentation observed in eyes without ocular hypertension. They concluded, "To our knowledge, to date, cases of ocular hypertension requiring treatment have not been discussed, making comparison impossible." However, Sanders et al[@b4-opth-10-1059] reported two eyes out of 526 (0.4%) with increased IOP requiring treatment at 3 years postoperative. In the context of ICL implantation, it is important to remember that myopia alone is a well-established risk factor for glaucoma.[@b57-opth-10-1059]

Endothelial cell loss
=====================

Corneal health has remained an important long-term safety concern for patients undergoing intraocular procedures, although its relationship to ICL vault is unknown. Several long-term studies have provided information on endothelial cell density (ECD) following ICL implantation.

Moya et al[@b58-opth-10-1059] have published a cumulative 12-year retrospective study including data from 144 eyes implanted with ICLs between 1998 and 2001. Given the long period of follow-up, to avoid bias due to "\[...\] variability of the population attending a particular follow-up visit, it was not the mean ECD at each visit that was considered but rather the mean of the intra-subject variation of ECD considering each period of study."

Preoperative, first year, and last visit mean ECD were 2,586.61±320.14, 2,434.13±290.12, and 2,071.13±361.84 cells/mm^2^, respectively (Kruskal--Wallis test, *P*\<0.05). There were no corneal adverse events during the course of follow-up. The authors conclude, "\[...\] we can estimate a 6.46% surgically induced ECD decrease during the first year and an average yearly decrease rate of 1.20% after that."

The authors go on to state that a 30-year-old patient with a preoperative "\[...\] ECD of 2,586 cells/mm^2^ (mean preoperative value for age-matched patients included in our study) who had ICL implantation would reach 1,500 cells/mm^2^ (the threshold value below which explantation is recommended) at the age of 70 years (ie, 40 years after implantation)."

In a separate long-term study, Igarashi et al[@b11-opth-10-1059] reported 8-year follow-up on 41 eyes of 41 patients. They reported, "The mean percentage of endothelial cell loss was 6.2±8.6% (−24.5% to 22.8%) 8 years postoperatively."

There were no corneal adverse events reported. The authors commented, "In the current study, the mean percentage of endothelial cell loss was 6.2% 8 years postoperatively, which was considerably lower than the findings in previous studies."

Five year follow-up, reported by Alfonso et al,[@b13-opth-10-1059] demonstrated that the mean ECD decreased from 2,698±467 cells/mm^2^ preoperatively to 2,495±357 cells/mm^2^, representing a mean endothelial cell loss of 7.5%. The availability of long-term data from these studies is reassuring regarding the corneal health of patients implanted with the ICL.

Management of excessive or insufficient vault and related complications
=======================================================================

Close observation of ICLs with insufficient or excessive vault represents an important mitigation of vault-related adverse events, including cataract and glaucoma. However, given the variety of criteria and recommendations in the literature for the acceptable limits of vault, the decision to initiate close observation or replace an ICL due to insufficient or excessive vault in the absence of vault-related complications remains a matter of medical judgment. Furthermore, the development of ASC cataract, pigment dispersion, or elevated IOP not requiring treatment or amenable to treatment with topical medication does not in and of itself represent an indication for replacement or explantation, because "Some eyes with stable peripheral ASCC may never experience a loss of best-corrected visual acuity",[@b17-opth-10-1059] and IOP monitoring will address the "theoretical risk of pigmentary glaucoma" that "has not been realized yet."[@b19-opth-10-1059] As an example of the stable, nonvisually significant nature of many ASC opacities, Sanders[@b8-opth-10-1059] concluded that while approximately 6%--7% of eyes developed ASC opacities at 7+ years following ICL implantation, only 1%--2% progressed to clinically significant cataract during the same period.

While precise, objective measurement of vault with OCT is useful for research, for clinical purposes subjective slit lamp evaluation of postoperative vault (eg, using corneal thickness as a measure) is generally adequate to determine both the need for close follow-up and the indication for replacement. As Alfonso et al[@b38-opth-10-1059] have demonstrated, "Subjective and objective values of vault are highly correlated \[...\]. There was a statistically significant high correlation between subjective and objective values (Spearman rho; *r* =0.82; *P*\<0.001)."

Nevertheless, it is important to take into account both illumination and accommodation, which may impact the observed vault at any given time.

Reported outcomes following ICL replacement, although limited in number, support the utility of this procedure. Zeng et al,[@b18-opth-10-1059] for example, reported normalization of vault without concomitant morbidity in all 16 eyes undergoing replacement in their study: "\[...\] there were no surgical complications, such as significant endothelial cell loss or cataracts, after the pIOL exchange in our study."

Explantation is indicated in the setting of progressive, visually significant cataract, whether or not ICL related. Reports of ICL explantation, phacoemulsification cataract extraction, and posterior chamber intraocular lens implantation support the utility of this procedure. As Sanders[@b8-opth-10-1059] noted in his report, "Anterior Subcapsular Opacities and Cataracts 5 Years After Surgery in the Visian Implantable Collamer Lens FDA Trial," "\[...\] postoperative BSCVA compared to BSCVA before ICL implantation improved by 2 lines in 1 eye, 1 line in 3 eyes, and was unchanged in the remaining 3 eyes for an average improvement of 0.7 lines of BSCVA."

Kamiya et al[@b59-opth-10-1059] reported on a series of ten eyes of eight patients who underwent ICL explantation and cataract surgery 3.6±1.9 years (range, 1.6--7.4 years) after ICL implantation. One eye showed no change in best spectacle corrected visual acuity, two eyes gained 1 line, seven eyes gained 2 or more lines, and no eyes lost any lines. No adverse events, including increased IOP, posterior capsular opacity, cystoid macular edema, or retinal detachment, were seen at any time during the 3-month follow-up period. Regarding ICL explantation and cataract surgery, it should be noted that virtually all implanted ICLs will one day be explanted in the setting of age-related cataract, given the life expectancy and incidence of cataracts in the population of patients who are candidates for ICL implantation today. Fortunately, the results of cataract surgery in the setting of prior ICL implantation mirror the successful outcomes of today's routine cataract surgery.

V4c Visian ICL with KS Aquaport, VICMO
======================================

The VICMO ICL, which is currently available outside the United States, is a single-piece lens designed with a central convex/concave optical zone of 4.9 or 5.8 mm diameter and a 360 μm center optic port. The lens also contains four other 360 μm through-ports, two at the alignment marks (one at either side of the optic) and two on the footplates (one on the leading right haptic and one on the trailing left haptic). These ports are intended to facilitate removal of viscoelastic during surgery, reducing the risk of postoperative increases in IOP. In addition, the orientation holes on the right leading and left trailing foot plates have been enlarged from 110 to 360 μm to improve visualization of the holes and better aid lens orientation.

As with all Visian ICL models, the VICMO lens is produced from Collamer, a proprietary hydroxyethyl methacrylate/porcine-collagen-based biocompatible polymer material and an ultraviolet-absorbing chromophore. It has a refractive index of 1.442 at room temperature in balanced salt solution. The ICL is designed as a plate haptic lens with a central anterior convex surface with a concave posterior surface. The lens incorporates a forward vault designed to minimize contact with the central anterior capsule of the human crystalline lens. All Visian ICL models are capable of being folded and implanted through an incision of 3.5 mm or less.

In a preclinical study performed by Fujisawa et al,[@b60-opth-10-1059] 20 eyes of ten 3-month old miniature pigs were implanted with ICL lenses and the anterior segments were photographed at 1 week, 1 month, and 3 months after surgery. Evans Blue was infused into the vitreous at 3 months and then the eyes were enucleated, fixed, and examined. In the ICL without holes, ASC opacities were observed in all eyes, and the anterior surfaces of the crystalline lenses were not stained. Implantation of the ICLs with 3.0 mm holes resulted in light staining of the anterior surface of the lens. In these eyes, no subcapsular opacities were observed.

Shiratani et al[@b61-opth-10-1059] confirmed these findings in their study of ICLs with 1.0 mm central holes, noting that: "Unperforated ICLs cause cataracts, but placing a hole in the center of the optic appears to prevent the development of a secondary cataract. \[...\] The mechanism of cataract prevention is considered to be related to the aqueous humor circulation.[@b61-opth-10-1059]"

The VICMO ICL has been available in markets outside of the United States since 2011. Peer-reviewed scientific publications reporting overall clinical safety and effectiveness data following VICMO implantation are listed in [Table 4](#t4-opth-10-1059){ref-type="table"}. Each of these studies employed sizing methodology based on WTW and ACD measurements. Of note, the difference between vault of the V4c and other models without the central port, based on the publications listed in [Table 1](#t1-opth-10-1059){ref-type="table"}, is not statistically significant (two-sample two-sided *t*-test using pooled mean and standard deviations; *t* (2,594)= −1.70; *P*=0.09). The 95% CI for the difference (V4c minus others) is −3 to 42 μm.

To address concerns regarding the implications of the central port design on quality of vision, Perez-Vives et al[@b62-opth-10-1059] studied ICL models with and without the central port utilizing an adaptive optics simulator. No statistically significant differences in visual acuity or contrast sensitivity were found between the two models for any ICL powers and pupil sizes evaluated (*P*\>0.05). Regarding the effect of ICL decentration on visual performance, the authors did not find statistically significant differences in visual acuity or contrast sensitivity between centered, 0.3 mm decentered and 0.6 mm decentered lenses (*P*\>0.05). Moreover, decentration affected both lens models in the same manner. The authors concluded that both models of ICL provide good and comparable visual performance for all powers and pupil sizes evaluated, regardless of centration.

Effectiveness
=============

Measures of effectiveness include postoperative UCVA, MRSE, refractive predictability, and refractive stability.

Visual acuity outcomes are provided in [Table 5](#t5-opth-10-1059){ref-type="table"}. The efficacy index (postoperative UCVA divided by preoperative BCVA) is 1.00 or greater in all cases in which it was reported. A high percentage of eyes achieved and maintained 20/20 or better UCVA. In the study with the longest available follow-up, Shimizu et al[@b63-opth-10-1059] reported that: "The postoperative UDVAs of the Hole ICL group were 20/20 or better 1, 3, and 6 months and 1, 3, and 5 years postoperatively, in 97%, 100%, 100%, 100%, 100%, and 85% of eyes, respectively\[...\][@b63-opth-10-1059]"

Postoperative MRSE data are provided in [Table 6](#t6-opth-10-1059){ref-type="table"}. Mean absolute MRSE was less than 0.3 D in all studies for which it was reported. Excellent predictability is demonstrated by the high percentage of eyes achieving MRSE within 0.5 and 1.0 D of emmetropia. Postoperative refractive spherical equivalent has also been shown to vary little during the postoperative period.

Safety
======

Specific reported safety outcomes related to VICMO implantation include preservation of BCVA, changes in IOP, endothelial cell loss, quality of vision, and cataract. [Table 7](#t7-opth-10-1059){ref-type="table"} provides postoperative BCVA from studies with available data, while [Table 8](#t8-opth-10-1059){ref-type="table"} provides gain or loss of lines of BCVA. The majority of eyes maintained preoperative BCVA, while a significant proportion gained 1 or more lines.

The safety index is the ratio of postoperative to preoperative BCVA. Huseynova et al[@b64-opth-10-1059] noted that, "The safety index at 3 months was 1.07 (for Group I \[V4b\]) and 1.14 (for Group II \[VICMO\])". Lisa et al found a safety index of 1.04,[@b21-opth-10-1059] and Alfonso et al reported a safety index of 1.01.[@b65-opth-10-1059] The postoperative increase in BCVA is not unexpected, given the beneficial elimination of spectacle-related minification in moderate to severe myopia.

In the retrospective case series authored by Gonzalez-Lopez et al[@b66-opth-10-1059] of 100 eyes implanted with VICMO, no eye had an IOP greater than 30 mmHg at any postoperative measurement. In the retrospective cohort study authored by Higueras-Esteban et al,[@b67-opth-10-1059] which included 18 eyes implanted with VICMO, the authors noted "a mild and transient increase in IOP during the first month; however, no chronically elevated IOP levels or pupillary block were observed in either group." Lisa et al[@b21-opth-10-1059] noted, regarding their study of 147 eyes of 80 patients implanted with VICMO, "In the present study, we found no significant rise in IOP (\>20 mmHg) in any case, with stable IOP values during the 12-month follow-up \[...\].[@b21-opth-10-1059]"

[Table 9](#t9-opth-10-1059){ref-type="table"} provides data on ECD following implantation of VICMO. Authors generally employed minimum threshold ECD and ACD criteria for implantation similar to those found in the ICL labeling. The prospective study reported by Lisa et al[@b21-opth-10-1059] demonstrated a 1.7% decrease in ECD from baseline at 1 year. Shimizu et al[@b63-opth-10-1059] have provided the longest term follow-up of endothelial cell loss with VICMO, reporting that "The mean percentage of endothelial cell loss 5 years postoperatively was 0.5%±5.4%."

Shimizu et al[@b68-opth-10-1059] studied higher order aberrations, contrast sensitivity, and symptoms in a prospective, intraindividual investigation of 29 subjects. For 4 and 6 mm pupils, the changes after VICMO ICL implantation in coma-like aberrations, spherical-like aberrations, and total higher order aberrations were similar to those after ICL implantation (*P*\>0.05, Wilcoxon signed rank test). The postoperative area under the log contrast sensitivity function was significantly increased after VICMO implantation (*P*\<0.05) and was equivalent to that after ICL implantation under photopic, mesopic, and mesopic with glare conditions. Subjective symptoms such as glare or halo were also essentially equivalent after VICMO or ICL implantation.

These findings were echoed by Kamiya et al,[@b69-opth-10-1059] who concluded from an interindividual comparative study of modulation transfer function cutoff frequency, Strehl ratio, objective scattering index, and Optical Quality Analysis System values, using an optical quality analysis system, that VICMO: "Implantation appears to be essentially equivalent in the optical quality variables to conventional ICL implantation, suggesting that the presence of the central artificial hole does not significantly affect the optical quality and the intraocular scattering after surgery."

Huseynova et al[@b64-opth-10-1059] also found no significant difference in wavefront aberrations between VICMO and ICL subjects.

Eight of the twelve published studies on VICMO listed in [Table 4](#t4-opth-10-1059){ref-type="table"} specifically report the incidence of adverse events. These eight studies include data on 1,291 eyes followed for up to 5 years[@b63-opth-10-1059] and describe a zero incidence of asymptomatic ASC opacities, visually significant cataract, pupillary block, and pigment dispersion glaucoma.

Brar et al[@b44-opth-10-1059] have provided valuable additional data on the incidence of cataract over 5 years following ICL implantation in a total of 957 eyes, including 342 eyes implanted with the VICMO and 615 eyes implanted with the ICL. ICL explantation due to ICL-related cataract (ie, ASC cataract) was very low in this series, four out of 957 eyes (0.5%). All ICLs that were explanted due to cataract were the older ICL model. The authors note "No V4c ICL was explanted due to cataract in this series".

Results from preclinical and clinical studies of VICMO summarized in this review demonstrate that the addition of the central port maintains effectiveness equivalent to the FDA approved Visian ICL, and provides equivalent quality of vision and safety without the requirement for preoperative iridotomies. Additional follow-up is necessary to determine whether the more physiologic central port design will continue to improve the long-term safety profile of the ICL.

Conclusion
==========

In the decade since FDA approval, researchers have produced a large body of scientific evidence demonstrating the safety and effectiveness of the ICL and, more recently, VICMO. Although controversy has surrounded the methodology of sizing, meta-analysis of the peer-reviewed, scientific literature demonstrates that all currently reported techniques achieve similarly satisfactory results in terms of achieved vault. The reported rates of complications related to vault have generally remained low, except in those case series where additional risk factors such as higher levels of myopia and older age have impacted the incidence of cataract. Given the significant improvements in vision and quality of life made possible by the ICL, and the high degree of patient satisfaction associated with its use, the benefits of ICL implantation continue to outweigh the risks.
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![Forest plot providing means and 95% CI's for achieved vault in each study.\
**Notes:** The size of the mean bars is proportionate to the number of eyes represented, except for the two summary bars (All STS, All WTW/ACD) at the bottom. Confidence intervals were calculated from the reported means, standard deviations, and sample sizes. The overall standard deviations for the two bottom rows were calculated by pooling the standard deviations from the studies.\
**Abbreviations:** ACD, anterior chamber depth; STS, sulcus-to-sulcus diameter; CI, confidence interval; PTP, pigment end-to-pigment end diameter; WTW, white-to-white.](opth-10-1059Fig1){#f1-opth-10-1059}

![Pooled normal distribution of vault based on means and standard deviations of STS and WTW sizing methods.\
**Abbreviations:** STS, sulcus-to-sulcus diameter; WTW, white-to-white diameter.](opth-10-1059Fig2){#f2-opth-10-1059}

###### 

Studies with data on objective measurement of ICL vault (chronological order)

  Study                                           N (eyes/subjects)   Sizing method   Model       Mean vault microns ± SD (range)
  ----------------------------------------------- ------------------- --------------- ----------- ----------------------------------------------------
  Alfonso et al[@b38-opth-10-1059]                452/246             WTW/ACD         V4          414±228 (0--1,300)
  Seo et al[@b70-opth-10-1059]                    16/28               WTW/ACD         V4          440±330
  Kojima et al[@b71-opth-10-1059]                 36/19               WTW/ACD         V4          530±250
  Alfonso et al[@b13-opth-10-1059]                188/111             WTW/ACD         V4          364±198 mm (95% CI; 294--434)
  Dougherty et al[@b9-opth-10-1059]               73/73               STS             MICL        340±174 (90--952)
  Alfonso et al[@b35-opth-10-1059]                133/76              WTW/ACD         V4          439±231 (90--910)
  Alfonso et al[@b72-opth-10-1059]                323/196             WTW/ACD         V4          448±220 (100--1,060)
                                                  20/196                              TICMV4      493±161 (260--860)
  Sheng et al[@b24-opth-10-1059]                  54/29               WTW/ACD         Toric ICL   322.23±169.43 (48--487) (feet in sulcus, n=22)
                                                                                                  466.28±141.12 (140--680) (feet below sulcus, n=32)
  Kojima et al[@b26-opth-10-1059]                 81/43               STS/STSL        MICL        640±250 (190--1,330)
  Du et al[@b36-opth-10-1059]                     127/66              WTW/ACD         V4          392±173
  Reinstein et al[@b37-opth-10-1059]              50/25               STS             MICL        370±160 (80--920)
  Alfonso et al[@b65-opth-10-1059]                138/70              WTW/ACD         V4c         482.7±210.5 (90--970)
  Higueras-Esteban                                17/9                WTW/ACD         V4b         557±224 (95% CI; 442--672)
  et al[@b67-opth-10-1059]                        18/10               WTW/ACD         V4c         528±268 (95% CI; 354--635)
  Cao et al[@b73-opth-10-1059]                    62/31               WTW/ACD         V4          505±205 (149--892)
  Lee et al[@b74-opth-10-1059]                    54/28               WTW/ACD         V4          428.3±221.9 (60--1,090) \[photopic\]
                                                                                                  516.5±223.7 (130--1,230) \[mesopic\]
                                                  56/38               WTW/ACD         V4c         399.5±151.9 (110--960) \[photopic\]
                                                                                                  547.0±173.1 (210--1,060) \[mesopic\]
  Ghoreishi and Mohammadinia[@b41-opth-10-1059]   63/49               WTW/ACD         V4b         368.57±165.661 (100--750)
                                                                      STS             V4b         365.40±207.735 (110--1,010)
                                                                      STS/WTW         V4b         471±272.621 (80--1,000)
  Alfonso et al[@b75-opth-10-1059]                35/20               WTW/ACD         TV4b        594.3±155.9 (200--810)
  Gomez-Bastar et al[@b76-opth-10-1059]           349/216             WTW/ACD         V4/TV4      481±185 (100--1,090)
  Kamiya et al[@b77-opth-10-1059]                 23/23               WTW/ACD         V4b         459±239
                                                  23/23               WTW/ACD         V4c         482±245
  Lisa et al[@b5-opth-10-1059]                    121/68              WTW/ACD         V4b         458.2±217
  Lisa et al[@b21-opth-10-1059]                   147/80              WTW/ACD         V4c         405.5±184.7 (100--980)
  Malyugin et al[@b25-opth-10-1059]               29/16               PTP             MICL        530±180 (240--840)

**Abbreviations:** ICL, implantable collamer lens; SD, standard deviation; PTP, pigment end-to-pigment end diameter; WTW, white-to-white; ACD, anterior chamber depth; STS, sulcus-to-sulcus diameter; MICL, myopia implantable collamer lens; STSL, sulcus-to-sulcus plane to anterior crystalline lens distance.

###### 

Studies with objective data on vault also reporting safety outcomes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                       N (eyes)   Length of follow-up       ICL removal, replacement, reposition % (N eyes)   ASC opacities % (N eyes)   Cataract surgery % (N eyes)   Pupillary block % (N eyes)   Ocular hypertension or glaucoma % (N eyes)
  ------------------------------------------- ---------- ------------------------- ------------------------------------------------- -------------------------- ----------------------------- ---------------------------- --------------------------------------------
  Seo et al[@b70-opth-10-1059]                16         19.75±17.14 months\       NR                                                NR                         0                             NR                           NR
                                                         (range: 6--56 months)                                                                                                                                             

  Kojima et al[@b71-opth-10-1059]             36         1 year                    0                                                 0                          0                             0                            0

  Alfonso et al[@b13-opth-10-1059]            188        5 years                   0                                                 1.1 (2)                    0.5 (1)                       0                            0

  Sheng et al[@b24-opth-10-1059]              54         8.6±4.6 months\           3.7 (2)                                           0                          0                             0                            0
                                                         (range: 3--20 months)                                                                                                                                             

  Kojima et al[@b26-opth-10-1059]             81         3 months                  0                                                 0                          0                             0                            0

  Reinstein et al[@b37-opth-10-1059]          50         6.5±0.7 years\            0                                                 4.0 (2)                    0                             0                            NR
                                                         (range: 4.1--7.4 years)                                                                                                                                           

  Alfonso et al[@b65-opth-10-1059]            138        6 months                  0                                                 0                          0                             0                            0

  Higueras-Esteban et al[@b67-opth-10-1059]   35         3 months                  NR                                                NR                         NR                            0                            0

  Cao et al[@b73-opth-10-1059]                62         3 months                  0                                                 NR                         0                             0                            0

  Alfonso et al[@b75-opth-10-1059]            35         1 year                    0                                                 0                          0                             0                            0

  Gomez-Bastar et al[@b76-opth-10-1059]       349        47±31 months\             1.2 (4)                                           0                          0                             0                            0
                                                         (range: 3--127 months)                                                                                                                                            

  Kamiya et al[@b77-opth-10-1059]             46         1 year                    0                                                 0                          0                             0                            0

  Lisa et al[@b5-opth-10-1059]                121        1 year                    0                                                 0                          0                             0                            0

  Lisa et al[@b21-opth-10-1059]               147        1 year                    0                                                 0                          0                             0                            0

  Malyugin et al[@b25-opth-10-1059]           29         1 year                    0                                                 0                          0                             0                            0

  Total N                                     1,387                                0.4 (6)                                           0.3 (4)                    0.1 (1)                       0                            0
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ICL, implantable collamer lens; ASC, anterior subcapsular; NR, not reported.

###### 

Studies reporting long-term data on incidence of lens opacities and cataract surgery

  Study                                  N (eyes/subjects)   Follow-up   Opacities % (N eyes)   Surgical cataracts % (N eyes)   Comments                                                      
  -------------------------------------- ------------------- ----------- ---------------------- ------------------------------- ---------- ------ ----------- ---------- ---------- --------- ----------------------------
  Sanders[@b8-opth-10-1059]              311/NR              7 years     5.9 (31)               \(5\)                           0          0      1.3 (7)     0          0          0         
  Kamiya et al[@b78-opth-10-1059]        56/34               4 years     11 (6)                 0                               0          0      1.8 (1)     0          0          1.8 (1)   Traumatic cataract: 1 eye
  Schmidinger et al[@b17-opth-10-1059]   84/84 \[V4 ICL\]    6 years     28                     0                               NR         0      17          0          NR         0         Higher myopia
  Alfonso et al[@b13-opth-10-1059]       188/111             5 years     1.1 (2)                0                               0          0      0.5 (1)     0          0          0         
  Igarashi et al[@b11-opth-10-1059]      41/41               8 years     9.8 (4)                9.8 (4)                         0          0      NR          NR         NR         4.9 (2)   50% unrelated to ICL
  Lee et al[@b12-opth-10-1059]           281/145             7 years     2.1 (6)                0                               0          0      0           0          0          0         
  Alfonso et al[@b43-opth-10-1059]       3,420/1,898         6 years     NR                     NR                              NR         0      0.61 (21)   0.03 (1)   0.09 (3)   0         Combined cataracts: 4 eyes
  Brar et al[@b44-opth-10-1059]          957/NR              5 years     NR                     NR                              NR         0      0.4 (4)     0.2 (2)    0.2 (2)    0         50% unrelated to ICL
  Guber et al[@b56-opth-10-1059]         75/45               10 years    NR                     NR                              NR         54.8   NR          NR         NR         18.3      Higher myopia, older age
  Shimizu et al[@b63-opth-10-1059]       64/32               5 years     3.2 (1)                0                               0          0      0           0          0          0         

**Abbreviations:** NR, not reported; ICL, implantable collamer lens; ASC, anterior subcapsular; PSC, posterior subcapsular cataract; NS, nuclear sclerosis.

###### 

Publications reporting overall safety and effectiveness data for V4c with KS Aquaport, VICMO

  -------------------------------------------------------------------------------------------
  Study                                       N V4c\   N V4c\     Design
                                              eyes     patients   
  ------------------------------------------- -------- ---------- ---------------------------
  Shimizu et al[@b79-opth-10-1059]            20       20         Retrospective case series

  Shimizu et al[@b68-opth-10-1059]            29       29         Prospective comparison

  Alfonso et al[@b65-opth-10-1059]            138      70         Prospective case series

  Kamiya et al[@b69-opth-10-1059]             28       28         Retrospective comparison

  Higueras-Esteban et al[@b67-opth-10-1059]   18       10         Retrospective comparison

  Gonzalez-Lopez et al[@b66-opth-10-1059]     100      56         Retrospective case series

  Huseynova et al[@b64-opth-10-1059]          44       44         Retrospective comparison

  Kamiya et al[@b77-opth-10-1059]             23       23         Retrospective comparison

  Alfonso et al[@b43-opth-10-1059]            781      NR         Retrospective comparison

  Lisa et al[@b21-opth-10-1059]               147      80         Prospective case series

  Fernández-Vigo et al[@b80-opth-10-1059]     50       25         Prospective case series

  Shimizu et al[@b63-opth-10-1059]            32       16         Prospective case series
  -------------------------------------------------------------------------------------------

**Abbreviation:** NR, not reported.

###### 

Postoperative UCVA for V4c reported at final visit

  Study                                       logMAR UCVA
  ------------------------------------------- -----------------------------------
  Shimizu et al[@b79-opth-10-1059]            −0.20±0.12
  Alfonso et al[@b65-opth-10-1059]            0.009±0.062
  Kamiya et al[@b69-opth-10-1059]             −0.20±0.11 (95% CI, 0.03--0.42)
  Higueras-Esteban et al[@b67-opth-10-1059]   −0.07±0.11
  Huseynova et al[@b64-opth-10-1059]          −0.13±0.08 (Range: −0.30 to 0.10)
  Lisa et al[@b21-opth-10-1059]               0.028±0.055
  Fernández-Vigo et al[@b80-opth-10-1059]     0.05±0.11 (Range: 0.0 to 0.4)
  Shimizu et al[@b63-opth-10-1059]            −0.17±0.14 (Range: −0.30 to 0.15)

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** UCVA, uncorrected visual acuity; CI, confidence interval.

###### 

Postoperative MRSE for V4c

  ------------------------------------------------------------------------------------------------------------
  Study                                       Postop MRSE D             \% within ±0.50 D   \% within ±1.0 D
  ------------------------------------------- ------------------------- ------------------- ------------------
  Alfonso et al[@b65-opth-10-1059]            0.03±0.19                 98.6                100

  Kamiya et al[@b69-opth-10-1059]             −0.03±0.20\                                   
                                              (95% CI, −0.42 to 0.37)                       

  Higueras-Esteban et al[@b67-opth-10-1059]   −0.3±0.5                                      

  Huseynova et al[@b64-opth-10-1059]          0.19±0.40\                75                  98
                                              (Range: −0.75 to 1.13)                        

  Lisa et al[@b21-opth-10-1059]                                         93.9                100

  Fernández-Vigo et al[@b80-opth-10-1059]     0.01±0.15\                                    
                                              (Range: −0.375 to 0.75)                       
  ------------------------------------------------------------------------------------------------------------

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** MRSE, manifest refractive spherical equivalent; Postop, postoperative; CI, confidence interval.

###### 

Postoperative logMAR BCVA for V4c reported at final visit

  Study                                     BCVA
  ----------------------------------------- -------------------------------------
  Alfonso et al[@b65-opth-10-1059]          −0.015±0.032
  Kamiya et al[@b69-opth-10-1059]           −0.26±0.06 (95% CI, −0.38 to −0.14)
  Huseynova et al[@b64-opth-10-1059]        −0.18±0.04 (Range: −0.30 to −0.08)
  Lisa et al[@b21-opth-10-1059]             0.003±0.013
  Fernández-Vigo et al[@b80-opth-10-1059]   0.04±0.10 (Range: 0.0 to 0.2)
  Shimizu et al[@b63-opth-10-1059]          −0.24±0.08 (Range: −0.30 to −0.08)

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** BCVA, best corrected logMAR visual acuity; CI, confidence interval.

###### 

Lines gained or lost, n (%)

  Study                                Lost 2   Lost 1   No change    Gained 1    Gained 2   Gained 3 or more
  ------------------------------------ -------- -------- ------------ ----------- ---------- ------------------
  Alfonso et al[@b65-opth-10-1059]     0        0        113 (81.9)   21 (15.2)   4 (2.9)    0
  Huseynova et al[@b64-opth-10-1059]   0        0        24 (55)      16 (36)     3 (7)      1 (1)
  Lisa et al[@b21-opth-10-1059]        0        0        116 (78.9)   21 (14.3)   5 (3.4)    5 (3.4)
  Shimizu et al[@b63-opth-10-1059]     0        4 (15)   9 (35)       11 (42)     2 (8)      0

###### 

Endothelial cell loss reported for V4c

  Study                                     Time point   Percent change
  ----------------------------------------- ------------ ----------------
  Huseynova et al[@b64-opth-10-1059]        3 months     +0.01
  Fernández-Vigo et al[@b80-opth-10-1059]   3 months     −6.8
  Shimizu et al[@b79-opth-10-1059]          6 months     −2.8
  Alfonso et al[@b65-opth-10-1059]          6 months     −8.5
  Lisa et al[@b21-opth-10-1059]             1 year       −1.7
  Shimizu et al[@b63-opth-10-1059]          5 years      −0.5±5.4
